Humacyte, Inc. HUMA 深 沪
等待开盘 03-30 09:30:00 美东时间
0.6756
-0.103
-13.21%
华盛通- 最 高0.7699
- 今 开0.7406
- 成交量 1458.62万股
- 最 低 0.6682
- 昨 收 0.7784
- 总市值 1.30亿
- 52周最高 2.93
- 市盈率 静 --
- 换手率 7.56%
- 52周最低 0.6682
- 委 比 -24.45%
- 总股本 1.93亿
- 历史最高 17.45
- 量 比 1.09
- 振 幅 13.07%
- 历史最低 0.6682
- 每 手 1
- 风险率 0.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
今天 11:49
BTIG Maintains Buy on Humacyte, Lowers Price Target to $3
BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $6 to $3.
03-27 22:39
Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
Humacyte Commences $20M Offering Of 25M Common Stock
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a securities
03-19 20:35
Humacyte Receives $1.475M Commitment Of Symvess Acellular Tissue Engineered Vessel For Facilitation Of Hospitals In Saudi Arabia
Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has received a minimum purchase
03-19 20:34
Humacyte Reports Data Evaluating Symvess In Extremity Arterial Trauma Patients
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of long-term data
02-18 21:15
美股牛股 | 华仕伯大涨超34%！有望获Transocean以58亿美元收购；Playboy涨超33%
华仕伯大涨超34%！有望获Transocean以58亿美元收购，打造领先海上钻井巨头；Playboy涨超33%，拟1.22亿美元出售50%中国业务；脉冲生物科学涨超16%>>
02-10 15:18
美股大行评级 | 生化基因(BIIB)获10家大行上调目标价！Hims & Hers Health遭花旗下调目标价从30美元降至16.5美元
今日重点评级关注：瑞杰金融：上调Lumexa Imaging Holdings评级至"强力买入"，目标价23美元；BTIG：维持Transocean"买入"评级，目标价从6美元升至10美元
02-10 10:29
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.
02-10 03:30
美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
